DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Exposure: "DMHI has previously announced that they will be attending the North American Spine Society 11th Annual Evidence & Technology Spine Summit on February 26, 2015. This is the only winter meeting of its kind, providing both surgical and medical/interventional perspectives on current or emerging technology and techniques in spine care. Interesting to see what comes of this exposure....
PICK YOUR COMPANIES WELL. THEY HAVE TO BE LEGIT (NO SCAMS). THEN BUY WHEN EVERYONE IS SELLING AND SELL WHEN EVERYONE IS BUYING. TAKES PATIENCE.
Were any of you here back in July when FLXP did the 10,000:1 RS? You wouldn't forget it if you were. This company could care less about shareholders. They will absorb what you give them. Wouldn't be surprised if the RS again. Flexpower basically took 10,000 dollars straight outta my pocket. These dudes are greedy.
Still loading. They are the experts and if they have invested 15 years into their drug line, I believe their actions speak louder than any pps (which reflects the waxing and waning confidence of investors who may or may not have a clue of what the Propanc drug line is capable of in terms of revolutionizing the treatment of metastatic cancer).
Quality People + Product = Success
insert-text-here
Video: More from John Smythe on his book on ecancer tv
He's built an oncology practice at University of Edinburgh over 30 years. This guys will see PRP all the way through to licensing with big Pharma or Propanc's own share of the marketplace. Can't wait to see. BUY IN NOW! This is gonna take off. Big new coming, IMO. But do your own DD!
insert-text-here
Video: Propanc's John Smythe on ODD. He knows what he's talking about.
IMO, PRP will get ODD very soon.
insert-text-here
Im with you KngmAz. Propanc is not going to "fall out." This company is going to make it. It's just a matter of time. PRs will come, human trials will come, license agreements will be made, the Propanc drugline will go to market and the PPS will climb. Now is the time to buy, as evryonoe else runs scared, they leave their profits behind for us to accumulate. It all comes down to instant versus delayed gratification.
I would if I could but I'm already all in.
Wish I knew. Some serious volatility.
Nice entry point! Well done.
Well, first we need to get over the .02-.03. Once we see a nickle, this will really start trading. Te investor presentation shows Human trials at end of 2015. But my guess is we start seeing some PR about drug pipeline and FDA approval process earlier than that (especially if PRP gets ODD approval). Once that hits, it'll grab more investors and PPCH will see some serious volume action. My hope is that by May 2015, we are at .25. My hope!
Volume is down today.Bid sitter at .01.
When people start hitting the ask, this will fly.
The value of Propanc is still too abstract for some; at this price, it is a steal.
We wait patiently for human trials get underway, ODD status from FDA is coming,IMO; this will fly to 52 week high in no time.
Nice close at day high!
Slap the ask: not a bad price for 287,000 shares.
IMO, CEO is getting reading to make some strong moves. The conference in late Feb should be telling. DMHI PPS is reactive now, imagine if DMHI gains a market in the mobile EMR industry. It could skyrocket!!!!!!!!!!!!
Logic says we are back to 52 week high within 1-2 months. By then, Propanc should get word from FDA on ODD status. Would love to see this stock trading at .46. Propanc is that valuable. Once NITE get out the way, we are heading there. Can't wait.
Logic says we are back to 52 week high within 1-2 months. By then, Propanc should get word from FDA on ODD status. Would love to see this stock trading at .46. Propanc is that valuable. Once NITE get out the way, we are heading there. Can't wait.
higher lows, although good time to jump in. My prediction is next week we see .02+
The trend for Propanc has been the same for the past three weeks. Thursday and Fridays, your balance will be down, and Monday it climbs back to the teens.
RIght now is a crucial time.
We all need stay frustrated with NITE as they manipulate this stock and not fear them. DO NOT BE AFRAID OF THEIR POWER> IT IS LIMITED AND IT"S LIMIT IS YOUR WILLINGNESS TO KEEP YOUR SHARES AND SET YOUR ASK HIGH.
NITE will make you want to sell and that's how they get rich while you'll break even, make a buck or two or even count yourself lucky to have lost "only so much" (i've been there and it sucks). Stay frustrated with and not fearful of NITE.
Hold your positions, set your ask high and we will break through. Don't let NITE or the MM's rent space in your head or take control of your emotions. We will see Propanc through and it will reach dollar land. Hold on. Be Stalwart and unflinching in the daily swings. Any if you've got the money, buy on low asks, and then set your ask HIGH, Propanc will climb.
If nite would get out the way, a strong gust of wind would send us to silvers.
Good te to buy$$$% its on Sale!!!!!
Pfizer did not find a "cure." It found a treatment for breast cancer in a very limited population of post-menopausal women. This should in no way detract from what Propanc is doing, their target cancer(s) are of a much wider range, thier drug mechnaism of action is entirely different and their target treatable population is much larger. Rember Propanc's drugs are patented. Forget Pfizer, GO PROPANC!
FYI: Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells. Ibrance is intended for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole, another FDA-approved product used to treat certain kinds of breast cancer in postmenopausal women.
LET LIGHT ABOLISH THE NITE. AMEN.
And now that kindo got his 800,000 we should be good to go once light abolishes the NITE:)
What we need for Propanc to FLY: Enlightened self-interest, a philosophy in ethics which states that persons who act to further the interests of the group to which they belong, ultimately serve their own self-interest
Slap the ask! When we say AMEN, you'll be rich whether you bought in at .0165 or .0125
Patience is a virtue, my friend. Your proposition perpetuates the problem of our collective predicament.
yup, put up the sails....
2.2 Milly- Slap the ask; in the end it won't matter, you'll still be rich! And we can get this show underway:)
Look at the post just beneath yours:) It answers your question. MMs are the only one's with ask prices below .016!
Propanc May Go for ODD for PRP: HUGE!
I've been having some private message conversations with Propanc Message Board Posters about Propanc getting ODD for it's drug line or at least PRP alone, and the implications of this for PPCH PPS.
I wanted to pass along some of my own DD on this potential ODD for Propanc.
First off, according to Professor Klaus Kutz, “Once we have assessed and identified the most effective dose in animals, we plan to meet with the FDA (Food and Drug Administration), to discuss and agree upon the planned formal preclinical program to support an Investigational New Drug Application (IND) to commence human trials in 2015," said Professor Klaus Kutz, Chief Medical Officer at Propanc Health Group. "Depending on the final indication selected for our initial patient trials, we may also seek Orphan Drug Designation for our treatment given the novelty of our proenzyme formulation and depending on the size of the target patient population we propose for trials."[color=red][/color]
So what’s the big deal about ODD?
“The industry has rushed to develop orphan drugs in recent years because they cost their developers less to put through clinical trials, and command higher prices when they do launch. Trial sizes are naturally smaller than for diseases with large populations, and the lack of alternative treatments give orphan agents an advantage when up for regulatory review. Tax incentives reduce development costs further. And when orphan drugs do reach the market, on average their cost per patient is six times that of non-orphan drugs, a clear indication of their pricing power.”
Or as Stephen Rattner of NY Times put it, referring to the monstrous climb in the PPS of Jazz Pharmaceuticals, “to get drug developers to focus on these relatively small pools of patients, the federal government offers inducements like a 50 percent research-and-development tax credit as well as a longer period of market exclusivity (seven years after Food and Drug Administration approval, rather than the typical five). These long monopolies often give orphan drug makers a free hand to raise prices.”
http://opinionator.blogs.nytimes.com/2013/06/30/the-orphan-jackpot/
Other facts about ODD:
1. Worldwide orphan drug sales forecast to total 176 billion, almost double overall prescription market growth (excluding generics).
2. Orphan drugs set to be 19.1% of worldwide prescription sales by 2020 (excluding generics)
3. Median cost per patient differential 19 times higher for orphan drugs compared to non-orphan
4. Bristol-Myers Squibb set to climb to number one position in orphan drug sales to 2020
5. Phase III orphan drug development cost half that of non-orphan; potentially a quarter with US tax breaks
6. Phase III drug development time for orphan is no quicker than non-orphan
7. Orphan drug FDA approval time 10 months vs. 13 months for non-orphan
8. Expected return on investment of phase III/ filed orphan drugs 1.89 times greater than non-orphan drugs
See the link below for full Evaluation Report of 2014 Orphan Drugs:
insert-text-here
P.S. Image searching stock charts when ODD is announced show immediate blast-offs. Check it out.
Volume moving up today. DMHI is starting to attract attention today. Hopefully this continues. Great company with value IMO>
Taken together, the evidence says PPCH will be on the move up. Just a matter of time...the waiting is the hardest part.
Voice Recognition Software: This didn't make much of a dent when announced but the value added through strategic partnership with Rapid Improvement Inc., a voice recognition software, insert-text-here is just another value added component of DMHI.
One very innovative partnership is with Rapid Improvement, Inc., a Natural Language Processing (NLP) technology company in Washington, D.C. This is unique to the Virtual Physicians Network mobile platform and sought after by numerous EMR companies. Possible buyout of DMHI IMO, or new partnerships are around the corner.
darva,
Where did you get the information about R/S?
Agree here. They are a solid company. The CEO, george England, seems to be working on making connections and grabbing a share in the EMR market. Hopefully soon, we start to see some more PR as DMHI finds its place in the health information technology marketplace.
I totally hear that. It's a long term hold stock, waiting for some big news. I'm sitting with my shares and waiting for George England to make some moves that will draw attention and increase volume. It's a good price to buy in at, and seems to be holding around here. The Company has potential but needs to start generating more revenue; essentially, their product needs a share in the EMR mobile EMR market. We'll just have to wait and see.
Welcome to the new posters: I see there are a number of new posters here today. Welcome to the PPCH message board. Check out the stickie for PPCH's latest investor presentation (01/2015). This is a serious company with a scientific board with very admirable experience and expertise. Additionally, Propanc's Board of Directors is committed to "maximizing shareholder value," according to the Mr. Nathanielsz, Executive Chairman of Propanc and we have seen nothing to indicate otherwise. Side-note: any references to Propanc being a SCAM will be simply overlooked and will carry no weight on this board. Anyways, welcome aboard. This ship is getting ready for takeoff. Let's make it happen. Last PR was on 1/13/2015 and we are awaiting more. The investor presentation (sticky) includes a thorough overview of Propanc R&D (over past 8 years) as well as their plan for the coming year. In short, we have Animal studies demonstrating safety and efficacy and limited human trials demonstrating the same. Clinical trials should be underway this year. Right now this company has huge potential, and IMO and based on my DD, this potential will be realized.